anti-Etanercept ELISA Kit (Enbrel®) (ab237661)
Key features and details
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (qualitative)
- Reacts with: Human
Overview
-
Product name
anti-Etanercept ELISA Kit (Enbrel®)
See all Etanercept kits -
Detection method
Colorimetric -
Sample type
Serum, Plasma -
Assay type
Sandwich (qualitative) -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
anti-Etanercept ELISA Kit (Enbrel®) (ab237661) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Etanercept in biological matrices such as human serum and plasma.
Etanercept (Enbrel®) is a therapeutic fusion protein specific for Tumor Necrosis Factor-Alpha (TNF-α) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Etanercept specifically binds to TNF alpha and blocks its interaction with cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Assay Buffer 1 x 12ml Micro ELISA Plate 1 unit Negative Control 1 x 1ml Peroxidase Conjugate 1 x 12ml Plate sealers 2 units Positive Control 1 x 0.3ml Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash buffer (20X) 1 x 50ml -
Relevance
Etanercept (Enbrel®) is a therapeutic fusion protein specific for Tumor Necrosis Factor-Alpha (TNF-a) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Etanercept specifically binds to TNF alpha and blocks its interaction with cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.
